A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel with MORAb-004 in Metastatic Soft Tissue Sarcoma
The purpose of the study is to compare the effects, good and bad, of the study drug (MORAb-004) in combination with gemcitabine and docetaxel with gemcitabine and docetaxel alone.
Locally advanced unresectable or metastatic soft tissue sarcoma
Age 18 or over diagnosed with locally advanced unresectable or metastatic soft tissue sarcoma with no, one, or two prior systemic treatments. Blood work, imaging, and heart scans will be performed to determine eligibility upon consent.
18 - 120
Healthy Volunteers Needed
Duration of Participation
Treatment will last for as long as the participant is seeing clinical benefit.